Amedisys reported a significant increase in net income attributable to Amedisys, Inc. to $61.0 million in Q1 2025, up from $14.4 million in Q1 2024, primarily driven by a $48.1 million gain on an equity method investment. Net service revenue also increased to $594.8 million from $571.4 million in the prior year.

Amedisys reported a net service revenue increase to $598.1 million in Q4 2024, up from $570.8 million in Q4 2023. However, the company experienced a net loss attributable to Amedisys, Inc. of $20.4 million, or $0.62 per diluted share, primarily due to merger-related expenses and a non-cash goodwill and other intangibles impairment charge.

Amedisys reported a net service revenue increase of $31.5 million to $587.7 million compared to the previous year. Net income attributable to Amedisys, Inc. was $16.9 million, inclusive of merger-related expenses. Adjusted net income per diluted share was $1.00, compared to $0.98 in the prior year.

Amedisys, Inc. reported its financial results for the three months ended June 30, 2024. Net service revenue increased to $591.2 million compared to $553.0 million in 2023. Net income attributable to Amedisys, Inc. was $32.3 million, compared to a net loss of $80.3 million in 2023. Adjusted net income per diluted share was $1.32, compared to $1.37 in 2023.

Amedisys reported a mixed performance for Q1 2024. Net service revenue increased to $571.4 million, but net income decreased to $14.4 million due to merger-related expenses. Adjusted EBITDA and adjusted net income showed improvements compared to Q1 2023.

Amedisys reported a slight increase in net service revenue for Q4 2023, but net income was negatively impacted by merger-related costs. The company's adjusted EBITDA also saw a decrease compared to the previous year.

Amedisys reported a slight decrease in net service revenue to $556.2 million, compared to $558.0 million in the same quarter of the previous year. Net income attributable to Amedisys, Inc. increased to $26.0 million from $25.6 million in 2022. Adjusted net income per diluted share was $0.98, down from $1.15 in the prior year.

Amedisys, Inc. reported a decrease in net service revenue to $553.0 million compared to $557.9 million in 2022. The company experienced a net loss attributable to Amedisys, Inc. of $80.3 million, inclusive of merger-related costs, contrasting with a net income of $29.6 million in the previous year. Adjusted EBITDA was $74.6 million, slightly up from $74.4 million in 2022.

Amedisys reported a slight increase in net service revenue to $556.4 million, but net income decreased to $25.2 million. However, adjusted EBITDA and EPS exceeded internal expectations. The company updated its 2023 guidance, projecting adjusted net service revenue between $2.254 billion and $2.274 billion, adjusted EBITDA between $235 million and $245 million, and adjusted diluted EPS between $4.14 and $4.36.

Amedisys reported a slight increase in net service revenue to $562.0 million for Q4 2022, compared to $559.3 million in 2021. Net income attributable to Amedisys, Inc. was $31.7 million, slightly lower than the $34.0 million reported in the same period last year. The company also announced the sale of its personal care line of business and a palliative care partnership with BlueCross BlueShield of Tennessee.

Amedisys reported a net service revenue increase of $4.5 million to $558.0 million compared to $553.5 million in 2021. Net income attributable to Amedisys, Inc. was $25.6 million compared to $45.0 million in 2021, with adjusted diluted earnings per share of $1.15 compared to $1.53 in 2021.

Amedisys reported a decrease in net service revenue to $557.9 million compared to $564.2 million in 2021, and net income attributable to Amedisys, Inc. decreased to $29.6 million from $80.1 million in the previous year. The company is updating its previously issued revenue guidance: Adjusted net service revenue is anticipated to be in the range of $2.290 billion to $2.310 billion.

Amedisys reported a slight increase in net service revenue to $545.3 million, but net income decreased to $31.7 million. The company reaffirmed its 2022 guidance, anticipating adjusted net service revenue between $2.330 billion and $2.365 billion.

Amedisys reported a slight increase in net service revenue for Q4 2021, rising to $559.3 million from $550.7 million in the same period of 2020. However, net income attributable to Amedisys, Inc. decreased to $34.0 million compared to $45.2 million in the previous year. The company issued 2022 guidance, anticipating adjusted net service revenue to be in the range of $2.330 billion to $2.365 billion and adjusted EBITDA in the range of $275 million to $285 million.

Amedisys reported a slight increase in net service revenue to $553.5 million for the third quarter of 2021, compared to $544.1 million in 2020. However, net income attributable to Amedisys, Inc. decreased to $45.0 million from $72.0 million in the previous year, which included a $24.0 million income tax benefit related to executive stock option exercise. The company updated its 2021 guidance, anticipating adjusted net service revenue in the range of $2.200 billion to $2.205 billion and adjusted diluted earnings per share between $5.88 and $5.93.

Amedisys reported a strong second quarter of 2021, with net service revenue increasing to $564.2 million and net income attributable to Amedisys, Inc. reaching $80.1 million. The company closed the acquisition of Contessa Health and expanded its credit facility to $1 billion. A new $100 million share repurchase program was also authorized.

Amedisys reported a revenue increase of $45.4 million, reaching $537.1 million, and net income attributable to Amedisys, Inc. of $49.9 million. The company's Home Health segment showed strong momentum, while the Hospice segment continued to navigate COVID-19 challenges. Amedisys is focused on innovation, inorganic growth, and cash flow generation, positioning itself as a leader in industry consolidation.

Amedisys reported a revenue of $550.7 million and a net income of $45.2 million for Q4 2020. The company's adjusted EPS was $1.49, and they have issued 2021 guidance with revenue expected to be in the range of $2.275 billion to $2.315 billion.

Amedisys reported a net service revenue increase of $49.5 million to $544.1 million compared to 2019, and a net income attributable to Amedisys, Inc. of $72.0 million compared to $34.1 million in 2019. Adjusted net income attributable to Amedisys, Inc. was $74.6 million compared to $37.9 million in 2019. The company is integrating Aseracare and has paid down a portion of its debt.

Amedisys reported a decrease in net service revenue to $485.0 million compared to $493.0 million in 2019. Net income attributable to Amedisys, Inc. increased to $34.7 million compared to $33.7 million in 2019. The company reissued its full year 2020 guidance, anticipating net service revenue in the range of $2.040 billion to $2.070 billion and adjusted diluted earnings per share in the range of $4.84 to $5.06.

Amedisys reported a net service revenue increase of $24.4 million, reaching $491.7 million. Net income attributable to Amedisys, Inc. rose to $31.8 million, with diluted earnings per share at $0.96. The company withdrew its full-year 2020 guidance due to the uncertainty caused by COVID-19.

Amedisys reported a net service revenue increase of $66.3 million to $500.7 million for Q4 2019, compared to $434.4 million in 2018. Net income attributable to Amedisys, Inc. was $27.7 million, slightly up from $27.5 million in 2018. The company issued its 2020 guidance, anticipating net service revenue between $2.115 billion and $2.160 billion.